Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

ORATORIO Clinical Investigators; Xavier Montalban; Stephen L Hauser; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Giancarlo Comi; Jérôme de Seze; Gavin Giovannoni; Hans-Peter Hartung; Bernhard Hemmer; Fred Lublin; Kottil W Rammohan; Krzysztof Selmaj; Anthony Traboulsee; Annette Sauter; Donna Masterman; Paulo Fontoura; Shibeshih Belachew; Hideki Garren; Nicole Mairon; Peter Chin; Jerry S Wolinsky; Peter Wipfler

doi:10.1056/NEJMoa1606468

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

ORATORIO Clinical Investigators, Xavier Montalban, Stephen L Hauser, Ludwig Kappos, Douglas L Arnold, Amit Bar-Or, Giancarlo Comi, Jérôme de Seze, Gavin Giovannoni, Hans-Peter Hartung, Bernhard Hemmer, Fred Lublin, Kottil W Rammohan, Krzysztof Selmaj, Anthony Traboulsee, Annette Sauter, Donna Masterman, Paulo Fontoura, Shibeshih Belachew, Hideki GarrenNicole Mairon, Peter Chin, Jerry S Wolinsky, Peter Wipfler (Study group member)

Department of Neurology

Research output: Contribution to journal › Original Article › peer-review

1322 Citations (Web of Science)

Original language	English
Pages (from-to)	209-220
Journal	NEW ENGLAND JOURNAL OF MEDICINE
Volume	376
Issue number	3
DOIs	https://doi.org/10.1056/NEJMoa1606468
Publication status	Published - 2017

Keywords

DOUBLE-BLIND
MULTICENTER TRIAL
CANCER-RISK
CD20
DEMYELINATION
PATHOLOGY
ANTIBODY
DAMAGE

Access to Document

10.1056/NEJMoa1606468

Cite this

ORATORIO Clinical Investigators, Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Rammohan, K. W., Selmaj, K., Traboulsee, A., Sauter, A., Masterman, D., Fontoura, P., Belachew, S., ... Wipfler, P. (2017). Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. NEW ENGLAND JOURNAL OF MEDICINE , 376(3), 209-220. https://doi.org/10.1056/NEJMoa1606468

ORATORIO Clinical Investigators ; Montalban, Xavier ; Hauser, Stephen L et al. / Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. In: NEW ENGLAND JOURNAL OF MEDICINE 2017 ; Vol. 376, No. 3. pp. 209-220.

@article{d326c45af4d7480eacc5f63f5718f22f,

title = "Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis",

keywords = "DOUBLE-BLIND, MULTICENTER TRIAL, CANCER-RISK, CD20, DEMYELINATION, PATHOLOGY, ANTIBODY, DAMAGE",

author = "\{ORATORIO Clinical Investigators\} and Xavier Montalban and Hauser, \{Stephen L\} and Ludwig Kappos and Arnold, \{Douglas L\} and Amit Bar-Or and Giancarlo Comi and \{de Seze\}, J{\'e}r{\^o}me and Gavin Giovannoni and Hans-Peter Hartung and Bernhard Hemmer and Fred Lublin and Rammohan, \{Kottil W\} and Krzysztof Selmaj and Anthony Traboulsee and Annette Sauter and Donna Masterman and Paulo Fontoura and Shibeshih Belachew and Hideki Garren and Nicole Mairon and Peter Chin and Wolinsky, \{Jerry S\} and Peter Wipfler",

note = "Wipfler: study gr member, ohne Affiliation",

year = "2017",

doi = "10.1056/NEJMoa1606468",

language = "English",

volume = "376",

pages = "209--220",

journal = "NEW ENGLAND JOURNAL OF MEDICINE ",

issn = "0028-4793",

publisher = "Massachusetts Medical Soc",

number = "3",

}

ORATORIO Clinical Investigators, Montalban, X, Hauser, SL, Kappos, L, Arnold, DL, Bar-Or, A, Comi, G, de Seze, J, Giovannoni, G, Hartung, H-P, Hemmer, B, Lublin, F, Rammohan, KW, Selmaj, K, Traboulsee, A, Sauter, A, Masterman, D, Fontoura, P, Belachew, S, Garren, H, Mairon, N, Chin, P, Wolinsky, JS & Wipfler, P 2017, 'Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis', NEW ENGLAND JOURNAL OF MEDICINE , vol. 376, no. 3, pp. 209-220. https://doi.org/10.1056/NEJMoa1606468

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. / ORATORIO Clinical Investigators; Montalban, Xavier; Hauser, Stephen L et al.
In: NEW ENGLAND JOURNAL OF MEDICINE , Vol. 376, No. 3, 2017, p. 209-220.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

AU - ORATORIO Clinical Investigators

AU - Montalban, Xavier

AU - Hauser, Stephen L

AU - Kappos, Ludwig

AU - Arnold, Douglas L

AU - Bar-Or, Amit

AU - Comi, Giancarlo

AU - de Seze, Jérôme

AU - Giovannoni, Gavin

AU - Hartung, Hans-Peter

AU - Hemmer, Bernhard

AU - Lublin, Fred

AU - Rammohan, Kottil W

AU - Selmaj, Krzysztof

AU - Traboulsee, Anthony

AU - Sauter, Annette

AU - Masterman, Donna

AU - Fontoura, Paulo

AU - Belachew, Shibeshih

AU - Garren, Hideki

AU - Mairon, Nicole

AU - Chin, Peter

AU - Wolinsky, Jerry S

A2 - Wipfler, Peter

N1 - Wipfler: study gr member, ohne Affiliation

PY - 2017

Y1 - 2017

KW - DOUBLE-BLIND

KW - MULTICENTER TRIAL

KW - CANCER-RISK

KW - CD20

KW - DEMYELINATION

KW - PATHOLOGY

KW - ANTIBODY

KW - DAMAGE

U2 - 10.1056/NEJMoa1606468

DO - 10.1056/NEJMoa1606468

M3 - Original Article

C2 - 28002688

SN - 0028-4793

VL - 376

SP - 209

EP - 220

JO - NEW ENGLAND JOURNAL OF MEDICINE

JF - NEW ENGLAND JOURNAL OF MEDICINE

IS - 3

ER -

ORATORIO Clinical Investigators, Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. NEW ENGLAND JOURNAL OF MEDICINE . 2017;376(3):209-220. doi: 10.1056/NEJMoa1606468